eMIMS New Product
Shire launches Fosrenol
02-Apr-07
Shire has launched Fosrenol (lanthanum) for the treatment of hyperphosphataemia in chronic renal failure patients on haemodialysis, or continuous ambulatory peritoneal dialysis (CAPD).
Fosrenol inhibits the absorption of dietary phosphate by forming insoluble lanthanum phosphate complexes in the gastrointestinal tract. This leads to a reduction of serum phosphate levels.
Most patients can be managed with one tablet during each meal; patients who respond to lanthanum therapy usually achieve acceptable serum phosphate levels with 1500–3000mg daily.
Further information: Shire 01256 894000
Most patients can be managed with one tablet during each meal; patients who respond to lanthanum therapy usually achieve acceptable serum phosphate levels with 1500–3000mg daily.
Further information: Shire 01256 894000
Quick search - use * for an abbreviated search, eg nico*
Tools
Latest Guidelines
- Osteoporotic Fragility Fractures in Postmenopausal Women: Primary Prevention (NICE)
- Osteoporotic Fragility Fractures in Postmenopausal Women: Secondary Prevention (NICE)
- VTE, Prevention of: Dabigatran (NICE)
- Influenza Prophylaxis: Oseltamivir, Amantadine and Zanamivir (NICE)
- Hepatitis B, Chronic: Entecavir (NICE)
Comments
Only registered users may comment. Log in now or register for a free account.